Comparison of intermediate and high dose valaciclovir for the prophylaxis of CMV viraemia in allogeneic stem cell transplant recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78766104

Enrollment

110

Registered

2003-09-12

Start date

2002-07-03

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections and Infestations: Cytomegalovirus (CMV) infection Infections and Infestations Cytomegalovirus disease

Interventions

Randomised controlled trial.

Eligibility

Inclusion criteria

Inclusion criteria: 110 patients, 55 in each treatment arm.

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Rate of CMV viraemia 2. Time to CMV viraemia 3. Incidence of CMV disease 4. Survival	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026